417 related articles for article (PubMed ID: 28246756)
1. [First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO].
Rexer H; Bedke J
Urologe A; 2017 Mar; 56(3):385-386. PubMed ID: 28246756
[No Abstract] [Full Text] [Related]
2. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
[TBL] [Abstract][Full Text] [Related]
4. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
[TBL] [Abstract][Full Text] [Related]
5. Axitinib combination therapies versus sunitinib for renal cell carcinoma.
Stirrups R
Lancet Oncol; 2019 Mar; 20(3):e141. PubMed ID: 30799259
[No Abstract] [Full Text] [Related]
6. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
Chan A; Dang C; Wisniewski J; Weng X; Hynson E; Zhong L; Wilson L
Am J Clin Oncol; 2022 Feb; 45(2):66-73. PubMed ID: 34991104
[TBL] [Abstract][Full Text] [Related]
7. [An open single-arm phase II monotherapy study of pembrolizumab (MK-3475) in locally advanced/metastatic renal cell carcinoma (mRCC) (Keynote 427) - AN 40/16 of the AUO].
Rexer H; Doehn C; Bedke J
Urologe A; 2017 Jul; 56(7):928-929. PubMed ID: 28616640
[No Abstract] [Full Text] [Related]
8. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
Tamada S; Kondoh C; Matsubara N; Mizuno R; Kimura G; Anai S; Tomita Y; Oyama M; Masumori N; Kojima T; Matsumoto H; Chen M; Li M; Matsuda K; Tanaka Y; Rini BI; Uemura H
Int J Clin Oncol; 2022 Jan; 27(1):154-164. PubMed ID: 34800178
[TBL] [Abstract][Full Text] [Related]
9. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China.
Chen J; Hu G; Chen Z; Wan X; Tan C; Zeng X; Cheng Z
Clin Drug Investig; 2019 Oct; 39(10):931-938. PubMed ID: 31250401
[TBL] [Abstract][Full Text] [Related]
11. Combination Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Alam MU; Jazayeri SB; Gautam S; Norez D; Kumar J; Tanneru K; Nguyen S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
Am J Clin Oncol; 2020 Jul; 43(7):477-483. PubMed ID: 32251121
[TBL] [Abstract][Full Text] [Related]
12. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Motzer RJ; Penkov K; Haanen J; Rini B; Albiges L; Campbell MT; Venugopal B; Kollmannsberger C; Negrier S; Uemura M; Lee JL; Vasiliev A; Miller WH; Gurney H; Schmidinger M; Larkin J; Atkins MB; Bedke J; Alekseev B; Wang J; Mariani M; Robbins PB; Chudnovsky A; Fowst C; Hariharan S; Huang B; di Pietro A; Choueiri TK
N Engl J Med; 2019 Mar; 380(12):1103-1115. PubMed ID: 30779531
[TBL] [Abstract][Full Text] [Related]
13. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
[No Abstract] [Full Text] [Related]
15. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
Plimack ER; Powles T; Stus V; Gafanov R; Nosov D; Waddell T; Alekseev B; Pouliot F; Melichar B; Soulières D; Borchiellini D; McDermott RS; Vynnychenko I; Chang YH; Tamada S; Atkins MB; Li C; Perini R; Molife LR; Bedke J; Rini BI
Eur Urol; 2023 Nov; 84(5):449-454. PubMed ID: 37500340
[TBL] [Abstract][Full Text] [Related]
16. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
Motzer RJ; Robbins PB; Powles T; Albiges L; Haanen JB; Larkin J; Mu XJ; Ching KA; Uemura M; Pal SK; Alekseev B; Gravis G; Campbell MT; Penkov K; Lee JL; Hariharan S; Wang X; Zhang W; Wang J; Chudnovsky A; di Pietro A; Donahue AC; Choueiri TK
Nat Med; 2020 Nov; 26(11):1733-1741. PubMed ID: 32895571
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
[TBL] [Abstract][Full Text] [Related]
18. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.
Yan XQ; Ye MJ; Zou Q; Chen P; He ZS; Wu B; He DL; He CH; Xue XY; Ji ZG; Chen H; Zhang S; Liu YP; Zhang XD; Fu C; Xu DF; Qiu MX; Lv JJ; Huang J; Ren XB; Cheng Y; Qin WJ; Zhang X; Zhou FJ; Ma LL; Guo JM; Ding DG; Wei SZ; He Y; Guo HQ; Shi BK; Liu L; Liu F; Hu ZQ; Jin XM; Yang L; Zhu SX; Liu JH; Huang YH; Xu T; Liu B; Sun T; Wang ZJ; Jiang HW; Yu DX; Zhou AP; Jiang J; Luan GD; Jin CL; Xu J; Hu JX; Huang YR; Guo J; Zhai W; Sheng XN
Ann Oncol; 2024 Feb; 35(2):190-199. PubMed ID: 37872020
[TBL] [Abstract][Full Text] [Related]
19. [Risk-adapted therapy for metastatic renal cell carcinoma].
Grimm MO; Leucht K; Foller S; Grünwald V
Urologe A; 2020 Feb; 59(2):155-161. PubMed ID: 32006060
[TBL] [Abstract][Full Text] [Related]
20. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
Bracarda S; Bamias A; Casper J; Negrier S; Sella A; Staehler M; Tarazi J; Felici A; Rosbrook B; Jardinaud-Lopez M; Escudier B
Clin Genitourin Cancer; 2019 Jun; 17(3):e689-e703. PubMed ID: 31072748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]